vs
Side-by-side financial comparison of MONRO, INC. (MNRO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
MONRO, INC. is the larger business by last-quarter revenue ($293.4M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). MONRO, INC. runs the higher net margin — 3.8% vs 1.6%, a 2.2% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -4.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -2.7%).
Monro, Inc. is an automotive services company founded and headquartered in Rochester, New York, U.S. As of 2025, Monro has 1,260 locations making them the second-largest automotive services company in North America after Driven Brands by number of locations and by revenue.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MNRO vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $293.4M | $177.4M |
| Net Profit | $11.1M | $2.9M |
| Gross Margin | 34.9% | — |
| Operating Margin | 6.3% | 3.9% |
| Net Margin | 3.8% | 1.6% |
| Revenue YoY | -4.0% | 5.0% |
| Net Profit YoY | 143.1% | — |
| EPS (diluted) | $0.35 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $293.4M | $196.9M | ||
| Q3 25 | $288.9M | $179.5M | ||
| Q2 25 | $301.0M | $181.1M | ||
| Q1 25 | $295.0M | $168.9M | ||
| Q4 24 | $305.8M | $187.3M | ||
| Q3 24 | $301.4M | $168.6M | ||
| Q2 24 | $293.2M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $11.1M | — | ||
| Q3 25 | $5.7M | $5.4M | ||
| Q2 25 | $-8.1M | $-4.8M | ||
| Q1 25 | $-21.3M | $4.8M | ||
| Q4 24 | $4.6M | — | ||
| Q3 24 | $5.6M | $-143.5M | ||
| Q2 24 | $5.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 34.9% | 79.5% | ||
| Q3 25 | 35.7% | 80.9% | ||
| Q2 25 | 35.5% | 77.4% | ||
| Q1 25 | 33.0% | 79.7% | ||
| Q4 24 | 34.3% | 78.7% | ||
| Q3 24 | 35.3% | 76.9% | ||
| Q2 24 | 37.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 6.3% | 1.2% | ||
| Q3 25 | 4.4% | 3.5% | ||
| Q2 25 | -2.0% | 4.7% | ||
| Q1 25 | -8.1% | 1.2% | ||
| Q4 24 | 3.3% | 13.2% | ||
| Q3 24 | 4.4% | -82.8% | ||
| Q2 24 | 4.5% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 3.8% | — | ||
| Q3 25 | 2.0% | 3.0% | ||
| Q2 25 | -2.7% | -2.7% | ||
| Q1 25 | -7.2% | 2.8% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 1.9% | -85.1% | ||
| Q2 24 | 2.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.35 | $0.05 | ||
| Q3 25 | $0.18 | $0.12 | ||
| Q2 25 | $-0.28 | $-0.11 | ||
| Q1 25 | $-0.74 | $0.10 | ||
| Q4 24 | $0.15 | $0.38 | ||
| Q3 24 | $0.18 | $-3.11 | ||
| Q2 24 | $0.19 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.9M | $144.3M |
| Total DebtLower is stronger | $45.0M | — |
| Stockholders' EquityBook value | $604.9M | $653.9M |
| Total Assets | $1.6B | $1.2B |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $4.9M | $238.4M | ||
| Q3 25 | $10.5M | $246.3M | ||
| Q2 25 | $7.8M | $445.9M | ||
| Q1 25 | $20.8M | $493.6M | ||
| Q4 24 | $10.2M | $484.6M | ||
| Q3 24 | $20.9M | $453.8M | ||
| Q2 24 | $18.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $45.0M | $372.2M | ||
| Q3 25 | $60.0M | $376.7M | ||
| Q2 25 | $71.5M | $580.5M | ||
| Q1 25 | $61.3M | $583.4M | ||
| Q4 24 | $59.3M | $585.3M | ||
| Q3 24 | $62.0M | — | ||
| Q2 24 | $112.0M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $604.9M | $693.1M | ||
| Q3 25 | $601.7M | $727.2M | ||
| Q2 25 | $604.9M | $757.8M | ||
| Q1 25 | $620.8M | $798.5M | ||
| Q4 24 | $648.9M | $778.3M | ||
| Q3 24 | $651.9M | $749.6M | ||
| Q2 24 | $654.4M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.7B | $1.6B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.07× | 0.54× | ||
| Q3 25 | 0.10× | 0.52× | ||
| Q2 25 | 0.12× | 0.77× | ||
| Q1 25 | 0.10× | 0.73× | ||
| Q4 24 | 0.09× | 0.75× | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.17× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | — |
| Free Cash FlowOCF − Capex | $9.1M | — |
| FCF MarginFCF / Revenue | 3.1% | — |
| Capex IntensityCapex / Revenue | 3.0% | — |
| Cash ConversionOCF / Net Profit | 1.60× | — |
| TTM Free Cash FlowTrailing 4 quarters | $49.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $17.8M | $43.7M | ||
| Q3 25 | $32.3M | $60.8M | ||
| Q2 25 | $-1.9M | $12.0M | ||
| Q1 25 | $28.9M | $35.5M | ||
| Q4 24 | $14.8M | $33.1M | ||
| Q3 24 | $62.6M | $53.9M | ||
| Q2 24 | $25.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $9.1M | $43.5M | ||
| Q3 25 | $26.6M | $57.0M | ||
| Q2 25 | $-9.3M | $9.3M | ||
| Q1 25 | $23.2M | $26.9M | ||
| Q4 24 | $7.9M | $31.0M | ||
| Q3 24 | $57.6M | $49.8M | ||
| Q2 24 | $16.8M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 3.1% | 22.1% | ||
| Q3 25 | 9.2% | 31.7% | ||
| Q2 25 | -3.1% | 5.1% | ||
| Q1 25 | 7.9% | 15.9% | ||
| Q4 24 | 2.6% | 16.6% | ||
| Q3 24 | 19.1% | 29.6% | ||
| Q2 24 | 5.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | 0.1% | ||
| Q3 25 | 2.0% | 2.2% | ||
| Q2 25 | 2.5% | 1.5% | ||
| Q1 25 | 1.9% | 5.1% | ||
| Q4 24 | 2.2% | 1.1% | ||
| Q3 24 | 1.6% | 2.4% | ||
| Q2 24 | 3.0% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.60× | — | ||
| Q3 25 | 5.71× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 3.23× | — | ||
| Q3 24 | 11.08× | — | ||
| Q2 24 | 4.37× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MNRO
| Tires | $150.2M | 51% |
| Maintenance | $73.5M | 25% |
| Brakes | $35.1M | 12% |
| Steering | $24.9M | 8% |
| Batteries | $6.2M | 2% |
| Exhaust | $3.2M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
